GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (OTCPK:NVSEF) » Definitions » EV-to-EBITDA

Novartis AG (Novartis AG) EV-to-EBITDA

: 10.73 (As of Today)
View and export this data going back to 1996. Start your Free Trial

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Novartis AG's enterprise value is $202,079 Mil. Novartis AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $18,832 Mil. Therefore, Novartis AG's EV-to-EBITDA for today is 10.73.

The historical rank and industry rank for Novartis AG's EV-to-EBITDA or its related term are showing as below:

NVSEF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.92   Med: 12.32   Max: 17.06
Current: 10.73

During the past 13 years, the highest EV-to-EBITDA of Novartis AG was 17.06. The lowest was 5.92. And the median was 12.32.

NVSEF's EV-to-EBITDA is ranked better than
60.76% of 706 companies
in the Drug Manufacturers industry
Industry Median: 13.805 vs NVSEF: 10.73

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-19), Novartis AG's stock price is $90.24. Novartis AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $7.100. Therefore, Novartis AG's PE Ratio for today is 12.71.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Novartis AG EV-to-EBITDA Historical Data

The historical data trend for Novartis AG's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novartis AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.01 13.25 6.07 12.92 11.67

Novartis AG Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.92 11.78 12.09 11.65 11.67

Competitive Comparison

For the Drug Manufacturers - General subindustry, Novartis AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novartis AG EV-to-EBITDA Distribution

For the Drug Manufacturers industry and Healthcare sector, Novartis AG's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Novartis AG's EV-to-EBITDA falls into.



Novartis AG EV-to-EBITDA Calculation

Novartis AG's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=202079.407/18832
=10.73

Novartis AG's current Enterprise Value is $202,079 Mil.
Novartis AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $18,832 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Novartis AG  (OTCPK:NVSEF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Novartis AG's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=90.24/7.100
=12.71

Novartis AG's share price for today is $90.24.
Novartis AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.100.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Novartis AG EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Novartis AG's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Novartis AG (Novartis AG) Business Description

Address
Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Novartis AG (Novartis AG) Headlines

From GuruFocus

This Overlooked Danger Could Tank Big Pharma Stocks

By Margaret Moran 09-01-2022

Top 5 2nd Quarter Trades of TEALWOOD ASSET MANAGEMENT INC

By GuruFocus Research GuruFocus Editor 07-20-2022